I-124 PET/CT versus conventional radioiodine imaging in differentiated thyroid cancer: a review.
I-124 PET/CT versus conventional radioiodine imaging in differentiated thyroid cancer: a review.
- 2019
Available online from MWHC library: August 2000 - present, Available in print through MWHC library: 1999 - 2006
BACKGROUND: Studies report a wide spectrum of I-124 PET/CT sensitivity and specificity in detection of differentiated thyroid cancer (DTC) lesions. This paper reviews the lesion detection rate of pretherapy I-124 PET/CT in different patient populations and further analyzes the factors for better detection on I-124 PET/CT. CONCLUSION: I-124 PET/CT is able to identify a greater number of foci compared to diagnostic I-131 scan. I-124 PET may have better detection compared to posttherapy I-131 scan in patients who are I-131 therapy naive, have less aggressive pathology or do not have disseminated lung metastases. Additional metastatic lesion detection by I-124 PET has significant clinical impact in the management of patients prior to I-131 therapy in some patients. METHODS: A literature search was performed using multiple different databases from 1996 to April 2018. Searches include MEDLINE, EMBASE, Northern Lights and handsearching. Two reviewers reviewed and extracted study data for I-124, I-123 and I-131 scans in DTC. RESULTS: This review includes four retrospective and ten prospective studies in which 495 DTC patients underwent I-124 and I-131 imaging; no studies made comparisons to I-123. In the reports that compared I-124 to diagnostic I-131scan, there were a total of 72 patients in whom120 lesions were detected on I-124 whereas only 52 were detected on diagnostic I-131 scan; in publications that compared I-124 to posttherapy I-131scan in 266 patients, 410 lesions were detected on I-124 whereas 390 were detected on posttherapy I-131 scan. Based on I-124 PET/CT in six studies, TNM staging was revised in 15-21% of patients and disease management was altered in 5-29% of patients.
English
1050-7256
10.1089/thy.2018.0598 [doi]
*Iodine Radioisotopes
*Positron Emission Tomography Computed Tomography/mt [Methods]
*Radiopharmaceuticals
*Thyroid Neoplasms/dg [Diagnostic Imaging]
*Tomography, X-Ray Computed/mt [Methods]
Humans
MedStar Health Research Institute
MedStar Washington Hospital Center
Library
Medicine/Endocrinology
Medicine/Nuclear Medicine
Journal Article
Available online from MWHC library: August 2000 - present, Available in print through MWHC library: 1999 - 2006
BACKGROUND: Studies report a wide spectrum of I-124 PET/CT sensitivity and specificity in detection of differentiated thyroid cancer (DTC) lesions. This paper reviews the lesion detection rate of pretherapy I-124 PET/CT in different patient populations and further analyzes the factors for better detection on I-124 PET/CT. CONCLUSION: I-124 PET/CT is able to identify a greater number of foci compared to diagnostic I-131 scan. I-124 PET may have better detection compared to posttherapy I-131 scan in patients who are I-131 therapy naive, have less aggressive pathology or do not have disseminated lung metastases. Additional metastatic lesion detection by I-124 PET has significant clinical impact in the management of patients prior to I-131 therapy in some patients. METHODS: A literature search was performed using multiple different databases from 1996 to April 2018. Searches include MEDLINE, EMBASE, Northern Lights and handsearching. Two reviewers reviewed and extracted study data for I-124, I-123 and I-131 scans in DTC. RESULTS: This review includes four retrospective and ten prospective studies in which 495 DTC patients underwent I-124 and I-131 imaging; no studies made comparisons to I-123. In the reports that compared I-124 to diagnostic I-131scan, there were a total of 72 patients in whom120 lesions were detected on I-124 whereas only 52 were detected on diagnostic I-131 scan; in publications that compared I-124 to posttherapy I-131scan in 266 patients, 410 lesions were detected on I-124 whereas 390 were detected on posttherapy I-131 scan. Based on I-124 PET/CT in six studies, TNM staging was revised in 15-21% of patients and disease management was altered in 5-29% of patients.
English
1050-7256
10.1089/thy.2018.0598 [doi]
*Iodine Radioisotopes
*Positron Emission Tomography Computed Tomography/mt [Methods]
*Radiopharmaceuticals
*Thyroid Neoplasms/dg [Diagnostic Imaging]
*Tomography, X-Ray Computed/mt [Methods]
Humans
MedStar Health Research Institute
MedStar Washington Hospital Center
Library
Medicine/Endocrinology
Medicine/Nuclear Medicine
Journal Article